PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 4, 2018Alzheimer s & Dementia668 citations

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

View Full Paper
MMMichelle M. MielkeCHClinton E. HagenJXJing Xu

Key Points

Key points are not available for this paper at this time.

Abstract

Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mielke et al. (2018) studied this question.

synapsesocial.com/papers/69dcd1230de68e8319e53a52https://doi.org/10.1016/j.jalz.2018.02.013
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The projected effect of risk factor reduction on Alzheimer's disease prevalence2011 · 2,693 citations
  2. 2Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)2003 · 9,210 citations
  3. 3Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease2005 · 209 citations
  4. 4Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach1988 · 22,914 citations
  5. 5Mayo's older americans normative studies: WAIS-R norms for ages 56 to 971992 · 454 citations